GLAXOSMITHKLINE AS
Score · fiscal year 2025
52of 100
How to read this: the company is ahead of 55 % of companies in the Morning class Large in the same sector in 2025. What does this mean?
Rank in the Morning class Large: 242 of 541 · What are Morning company classes?
Place in the whole sector: 10,706 of 23,065 · Handel
Profile
Cheetah · Sprinter
High profitability, lower solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 52 and solidity 45 out of 100 among companies in the Morning class Large in the same sector in 2025. Methodology
Against the sector
GLAXOSMITHKLINE AS is 2 points above the median for companies in the Morning class Large in the same sector in 2025.
Median score 50 among 541 companies.
Against companies in the Morning class Large in the same sector in 2025: operating margin 3.0% (median 2.5%) and equity ratio 28.0% (median 30.9%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 1,264 MNOK | 1,119 MNOK |
| Operating margin | 3.0% | 2.5% |
| Profit margin | 3.1% | 2.5% |
| Return on assets | 9.7% | 10.2% |
| Equity ratio | 28.0% | 30.9% |
| Debt-to-equity | 2.57 | 2.23 |
| Current ratio | 1.11 | 1.30 |
| Revenue growth | 21.6% | 6.9% |
| Revenue per employee | 17.08 MNOK | 12.49 MNOK |
The median and “ahead of” refer to companies in the Morning class Large in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 52, GLAXOSMITHKLINE AS does better than 55% of companies in the Morning class Large in the same sector (541 companies) in 2025.
Score 2023–2025
- GLAXOSMITHKLINE AS
- Median: companies in the Morning class Large in the same sector
GLAXOSMITHKLINE AS has a score of 52 for 2025, rank 10,706 of 23,065 in the sector.
Strongest: Growth: percentile 82 against peers, revenue growth 21.6% against a median of 6.9%.
Weakest: Liquidity: percentile 29 against peers, current ratio 1.11 against a median of 1.30.
Worth a closer look
- Strong growth with weak liquidity. Is the growth financed, or does it tie up capital the company does not have? Based on: revenue growth 21.6% (median 6.9%); current ratio 1.11 (median 1.30).
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
GLAXOSMITHKLINE AS had an operating margin of 3.0% and an equity ratio of 28.0% in 2025, and ranks 10,706 of 23,065 in Handel.
From 2024 to 2025: revenue grew by 22% and the equity ratio fell from 37.3% to 28.0%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 118 MNOK and 315 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 291 MNOK |
| EV/EBIT | 8.0 | 315 MNOK |
| P/B | 1.0 | 118 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
- watch
Strong growth with weak liquidity. Is the growth financed, or does it tie up capital the company does not have?
Based on: Revenue growth 21.6% (median 6.9%); Current ratio 1.11 (median 1.30).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 0.7% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 52 | weight 30% |
|---|---|---|
| Solidity | 45 | weight 25% |
| Liquidity | 29 | weight 15% |
| Growth | 82 | weight 15% |
| Consistency | 57 | weight 15% |
Durability: 57 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is GLAXOSMITHKLINE AS?
The operating margin was 3.0% in 2025, against a median of 2.5% among companies in the Morning class Large in the same sector. Return on assets was 9.7%.
How solid is GLAXOSMITHKLINE AS?
The equity ratio was 28.0% in 2025 (median 30.9%). Debt-to-equity was 2.57 (median 2.23).
What is the liquidity of GLAXOSMITHKLINE AS like?
The current ratio was 1.11 in 2025 (median 1.30).
How does GLAXOSMITHKLINE AS compare in Handel?
GLAXOSMITHKLINE AS ranks 10,706 of 23,065 in Handel for 2025. Among companies in the Morning class Large it is number 242 of 541. Revenue changed by 21.6% from the year before.
Group accounts
The company is registered as part of a group, but we have no group accounts for it. Group accounts are filed by the parent company, and open data does not say which company that is.
Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.
We do not show the group structure, because open data does not say who owns whom.
Public contracts
- Contracts awarded since 2024
- 0
- Total awarded value since 2024
- value not stated
| Date | Buyer | Notice | Value |
|---|---|---|---|
| 17 October 2022 | Folkehelseinstituttet | Vaksine mot rotavirus | 0.0 MNOK |
| 10 November 2020 | Folkehelseinstituttet | HPV-vaksine i barnevaksinasjonsprogrammet | 0.0 MNOK (framework) |
| 28 July 2020 | Folkehelseinstituttet | Heksavalent vaksine - Kombinasjonsvaksine mot difteri, tetanus, kikhoste, polio, Hib og hepatitt B | value not stated |
| 8 August 2018 | Folkehelseinstituttet | Pandemisk influensavaksine | value not stated |
Based on notices in Doffin. Does not show call-offs under framework agreements or purchases below the publication threshold. Values are as stated by the buyer.
Source: Doffin (DFØ), fetched 28 October 2026. Winners are matched on organisation number.
Contains data under the Norwegian licence for public data (NLOD 2.0) made available by Doffin/the Norwegian Agency for Public and Financial Management (DFØ). NLOD 2.0
From the Central Coordinating Register
- Org. no.
- 930606308
- Legal form
- AS · part of a group
- Sector
- Handel (46.460)
- Morning company class
- Large
- Employees
- 74 registered 10 October 2026
- Founded
- 25 August 1981 45 years in operation
- Share capital
- 0.95 MNOK
- Business address
- Drammensveien 288, 0283 OSLO
- Municipality
- Oslo rank 63–221 of 357 in Norway
- Latest accounts filed
- 2025
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Omur Akalin Erin
- Chair of the board
- Omur Akalin Erin
- Auditor
- DELOITTE AS
- Accountant
- AMESTO ACCOUNTHOUSE AS
- Accountant
- KPMG ACCOUNTING AS
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 27 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 60 | 59 | 52 | |
| Rank | 7,233 | 7,271 | 10,706 | |
| Operating margin | 2.8% | 3.2% | 3.0% | |
| Return on assets | 9.8% | 11.6% | 9.7% | |
| Equity ratio | 39.8% | 37.3% | 28.0% | |
| Current ratio | 1.20 | 1.17 | 1.11 | |
| Revenue growth | – | 15.0% | 21.6% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 903.1 MNOK | 1,038.8 MNOK | 1,263.6 MNOK |
| Operating profit | 25.4 MNOK | 33.3 MNOK | 38.0 MNOK |
| Profit before tax | 27.8 MNOK | 34.9 MNOK | 38.9 MNOK |
| Net profit | 20.7 MNOK | 26.2 MNOK | 29.1 MNOK |
| Financial expenses | 0.9 MNOK | 1.9 MNOK | 2.2 MNOK |
| Total assets | 292.0 MNOK | 316.7 MNOK | 421.5 MNOK |
| Current assets | 210.3 MNOK | 232.2 MNOK | 335.3 MNOK |
| Equity | 116.3 MNOK | 118.1 MNOK | 118.1 MNOK |
| Retained earnings | 115.3 MNOK | 117.2 MNOK | 117.2 MNOK |
| Total liabilities | 175.7 MNOK | 198.6 MNOK | 303.4 MNOK |
| Current liabilities | 175.7 MNOK | 198.6 MNOK | 303.4 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 27 October 2026, accounts id 6982726.
Further
Similar companies
- Berggård Amundsen & Co AS index 52, rank 10,641 · compare
- KAPPAHL AS index 52, rank 10,695 · compare
- NILLE AS index 52, rank 10,703 · compare
- NG SPAR INNLAND AS index 52, rank 10,747 · compare
- TEXCON AS index 52, rank 10,766 · compare